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 Abstract   
Objective: Angiopoietin-related growth factor (AGF) is associated with angiogenesis but it can also affect glucose 
and energy metabolism. The aim of the study was to determine AGF levels in gestational diabetes mellitus (GDM).
Materials and Methods: The study included 44 patients with GDM (GDM group) and 33 non-diabetic, healthy, 
women in the third trimester of pregnancy (control group). We analyzed serum levels of AGF and other biochemical 
and anthropometric markers in all subjects.
Results: The study revealed that serum AGF levels were significantly higher in patients with GDM (113.30±69.92 
ng/ml) than in controls (52.30±35.59 ng/ml), (p-value<0.001). Fasting glucose (117.59 vs. 82.18), homeostasis 
model of assessment - insulin resistance (HOMA-IR), (2.91 vs. 1.75) diastolic (74.20 vs. 70.00) and mean (89.09 
vs. 84.84) blood pressure were found to be significantly higher in the GDM group when compared to the control 
group (p-value<0.05). There was a significant positive association between AGF and HOMA-IR in the GDM group.
Conclusions: Although gestational diabetes mellitus can be a predictor of serum AGF level, further studies are 
needed to explain the physiologic roles of AGF in glucose metabolism.
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Introduction
Gestational	 diabetes	 mellitus	 (GDM)	 is	 defined	 as	 ‘any	
degree	 of	 glucose	 intolerance	 with	 onset	 or	 first	 recognition	
during	pregnancy	[1].	It	is	one	of	the	most	common	pregnancy	
complications.	 The	 overall	 incidence	 of	 3–6%	 has	 steadily	
increased	 over	 time	 [2,	 3].	 Although	 GDM	 is	 generally	
temporary, it is associated with serious health complications, 
both	for	mothers	and	babies	[4].	For	the	mother,	higher	rates	of	
hypertension	 and	 cesarean	 section	 are	 reported	 [5,	 6].	 For	 the	
infant,	immediate	risks	include	macrosomia	(birth	weight	>4kg),	
low	birth	weight	(<2.5	kg),	birth	injury	and	stillbirth	[5,	6].	The	
pathophysiology	of	gestational	diabetes	 involves	 abnormalities	
of	 insulin-sensitive	 tissue.	Beta-cell	 sensing	 of	 glucose	 is	 also	
abnormal	 and	 is	manifested	 as	 an	 inadequate	 insulin	 response	
for	a	given	degree	of	glycemia.	Women	with	gestational	diabetes	
have	 decreased	 insulin	 sensitivity	 in	 comparison	with	weight-
matched	 control	 groups	 [7].	 Gestational	 diabetes	 is	 associated	
with	 increased	 risks	 of	 poor	maternal	 and	 perinatal	 outcomes.	
In population studies, pregnant women with gestational diabetes 
have	 increased	 risk	 of	 pregnancy-associated	 hypertension	
compared	with	non-diabetic	women	[8].	
Angiopoietin-related	growth	factor	[(AGF),	or	angiopoietin-
like	protein-6	(ANGPTL6)]	is	known	to	be	a	novel	hepatokine	
that	modulates	angiogenesis	and	metabolism	[9].	AGF	directly	
antagonizes	 obesity	 and	 related	 insulin	 resistance.	 In	 addition,	
AGF	facilitates	increased	energy	expenditure	[10].
The	aim	of	the	study	is	to	investigate	whether	AGF	level	is	
affected	in	patients	with	gestational	diabetes	mellitus.
Material and methods
The	local	Ethical	Committee	approved	the	study	and	written	
informed	consent	authors	obtained	from	all	the	pregnant	women	
between	 19	 and	 39	 years	 of	 age.	 Forty-five	women	diagnosed	
with	 gestational	 diabetes	 (GDM	 group)	 and	 35	 non-diabetic,	
healthy,	third	trimester	pregnant	women	(controls)	were	included	
in	the	study.	After	determination	of	serum	AGF	levels,	1	subject	
from	the	GDM	group	and	two	subjects	from	the	control	group,	
who	showed	extremely	high	or	low	levels	of	serum	AGF,	were	
excluded.	Gestational	diabetes	was	diagnosed	according	 to	 the	
Carpenter	and	Coustan	criteria	[11].
We	 used	 a	 standardized	 questionnaire	 to	 collect	 details	
pertaining	 to	 their	 anthropometrics,	 family	 history,	 medical	
and	 obstetric	 history,	 and	 other	 relevant	 information.	 Each	
subject	 underwent	 a	 complete	 medical	 examination,	 as	 well	
as	 a	 hematological,	 hepatic	 and	 renal	 function	 analysis.	 None	
of	 the	 patients	 reported	 personal	 history	 of	 hypertension,	
thromboembolic disease, endocrine diseases or cardiovascular 
events.	 Body	 mass	 index	 (BMI)	 we	 calculated	 at	 the	 time	 of	
pregnancy	and	before	pregnancy	in	all	subjects.	Systolic	blood	
pressure	(SBP)	and	diastolic	blood	pressure	(DBP)	were	recorded.	
Mean	arterial	pressure	(MAP)	was	calculated	as	follows:	(MAP=	
DBP+	(SBP-DBP)/3).	
Study protocol
In the GDM and the control groups, peripheral venous 
blood	samples	were	drawn	between	8:00	am	and	10:00	am	after	
fasting	for	at	least	eight	hours	for	measurements	of	fasting	serum	
insulin,	plasma	glucose,	AGF	levels	and	liver-kidney	functions.	
Sera	obtained	from	all	subjects	were	separated	immediately by 
centrifugation	at	4,000	g	for	10	min	and	frozen	at	-80°C.	Serum	
insulin	 level	 was	 assayed	 by	 enzyme-linked	 immunoassay	
(ADVIA	 Centaur,	 Bayer,	 Tarrytown,	 NY,	 USA).	 The	 intra-
assay	 and	 total	 coefficients	 of	 variation	 were	 6.1%	 and	 7.1%	
respectively.	 Insulin	 resistance	 score	 was	 determined	 using	
homeostasis	 model	 assessment	 (HOMA-IR	 =	 fasting	 insulin	
(mU/L)	×	fasting	glucose	(mg/dL)×0.05551/22.5)	[12].	Glucose	
was	measured	using	the	hexokinase	method	at	Synchron	LX20	
systems	 (Beckman	 Coulter,	 Fullerton,	 Calif)	 with	 an	 intra-
measurement	coefficient	of	variance	of	0.92–1.54%.	Serum	levels	
of	AST	 (aspartate	 transaminase),	ALT	 (alanine	 transaminase),	
BUN	 (blood	urea	nitrogen)	 and	 creatinine	measurements	were	
performed	 using	 Synchron	 LX20	 systems	 (Beckman	 Coulter,	
Fullerton,	Calif)	with	the	original	Beckman	Synchron	LX	system	
reagents.	
The	 serum	ANGPTL6	 levels	 were	 measured	 by	 enzyme-
linked	immunosorbent	assay	(Uscn	Kit,	Life	Science	Inc.,	Wuhan,	
P.R.	China).	The	intra-assay	coefficient	of	variation	was	5.4%	at	
15.6	ng/mL,	4.8%	at	62.5	ng/mL,	and	3.1%	at	125.0	ng/mL.	The	
minimum	 detectable	 amount	 of	ANGPTL6	 was	 typically	 less	
than	5.8	ng/mL.	
 Streszczenie   
Cel: Czynnik wzrostu związany z angiopoetyną (AGF) jest odpowiedzialny za angiogenezy ale może też wpływać 
na metabolizm glukozy i energii. Celem tego badania była ocena poziomu AGF w cukrzycy ciążowej (GDM).
Materiał i metoda: Do badania włączono 44 pacjentki z GDM (tzw. grupa GDM) i 33 zdrowe ciężarne w trzecim 
trymestrze ciąży (grupa kontrolna). Zbadano poziom surowiczego AGF oraz inne biochemiczne i antropometryczne 
markery u wszystkich pacjentek.
Wyniki: Wykazano, że poziom surowiczego AGF był istotnie wyższy u pacjentek z cukrzycą ciążową (113,3±69,92 
ng/ml) niż w grupie kontrolnej (52,3±35,59 ng/ml), (p<0,001). Glukoza na czczo (117,59 vs 82,18), insulinooporność 
– wskaźnik HOMA (2,91vs 1,75), ciśnienie rozkurczowe (74,2 vs 70) i ciśnienie średnie (89,09 vs 84,84) były 
istotnie wyższe w grupie GDM niż w grupie kontrolnej (p<0,05). Znaleziono istotne pozytywne powiązanie między 
AGF a wskaźnikiem HOMA w grupie GDM.
Wnioski: Cukrzyca ciążowa może być czynnikiem predykcyjnym poziomu surowiczego AGF, jednak dalsze badania 
są konieczne aby ustalić rolę AGF w metabolizmie glukozy.
 Słowa kluczowe: czynnik wzrostu związany z angiopoetyną / białko ANGPTL6 / 
     / cukrzyca ciążowa / 
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All anthropometric and laboratory parameters were measured 
at	28-32	weeks.	All	patients	were	followed	up	to	the	term	of	the	
pregnancy;	 subjects	 with	 any	 diseases	 except	 diabetes	 in	 the	
GDM	 group	 and	 subjects	 with	 any	 diseases	 that	 complicated	
the	pregnancy	(preeclampsia,	endocrinologic	disease,	premature	
contractions,	etc)	were	excluded.	
Statistical Analyses
All	 data	were	 analyzed	using	SPSS	 software	 version	15.0	
(Chicago,	 IL,	 USA).	 The	 Kolmogorov-Smirnov	 test	 we	 used	
to	 determine	 normal	 distribution	 of	 all	 variables.	All	 variables	
are	reported	as	mean	±	standard	deviation.	Differences	between	
groups	 were	 evaluated	 with	 Student-T	 test.	 Correlations	 were	
performed	 using	 the	 Pearson’s	 correlation	 method.	 Linear	
regression	 analysis	 was	 also	 used.	 A	 p value	 of	 <0.05	 was	
considered	as	statistically	significant	in	all	analyses.
Results
General	baseline	characteristics	of	patients	with	GDM	and	
the	 control	 group	 are	 were	 summarized	 in	 the	 Table	 I.	 There	
was	 no	 difference	 between	 groups	with	 respect	 to	 age,	 parity,	
gestational	 age	 (weeks),	 weight	 (kg)	 in	 pregnancy	 and	 before	
pregnancy.	Mean	pre-gestational	BMI	and	gestational	BMI	were	
higher in the GDM group when compared to the control group 
but	not	significantly	(p>0.05).	There	was	no	difference	between	
the	groups	with	respect	to	systolic	blood	pressure	(mm	Hg),	but	
diastolic	 and	 mean	 blood	 pressures	 were	 significantly	 higher	
in	 the	GDM	group	 than	 in	 the	 control	 group	 (	 p<0.05).	Mean	
fasting	 blood	 glucose	 level	 (U/ml)	 and	HOMA-IR	 value	were	
significantly	higher	in	the	GDM	group	than	in	controls	(p<0.05).	
In	addition,	mean	AGF	level	(ng/ml)	was	significantly	higher	in	
the	GDM	group	than	in	the	control	group	(Table	I),	(p<0.05).
Simple correlations between serum AGF levels and 
biochemical and anthropometric markers were analyzed by 
Pearson’s correlation test within the control and the GDM groups 
(Table	II).	HOMA-IR	and	insulin	showed	positive	correlation	in	
the	GDM	group	(Table	II).	
To	determine	the	factors	affecting	serum	AGF	levels,	linear	
regression	analysis	was	performed	(Table	III).	Group,	HOMA-
IR	and	 insulin	were	analyzed	as	statistically	significant	 factors	
affecting	 the	AGF	 level.	AGF	 level,	 subjects	 with	 gestational	
diabetes	 and	 higher	 HOMA-IR	 value	 showed	 a	 positive	
association,	 whereas	 there	 was	 no	 significant	 association	with	
insulin	(p=	0.686),	(Table	III).
Table  I .  Characteristics of the study population.
CONTROL group  
(n=33)
GDM group   
(n=44) p-value
Age 27.63±4.44 28.43±4.66 .453
Gravidity 2.33±1.31 2.43±1.53 .768
Parity 1.06±1.08 1.38±1.45 .283
Gestational age, week 33.57±2.82 33.50±2.69 .905
Pregestational weight (kg) 63.84±8.89 66.13±9.81 .296
Gestational weight (kg) 72.36±11.80 77.54±12.25 .066
Pregestational BMI (kg/m2) 24.25±3.17 25.06±3.46 .297
Gestational BMI (kg/m2) 27.46±4.06 29.36±4.23 .051
Systolic blood pressure (mm Hg) 114.55±10.55 118.86±12.52 .114
Diastolic blood pressure (mm Hg) 70.00±8.92 74.20±8.27 .036*
Mean arterial pressure (mm Hg), 84.84±8.65 89.09±9.01 .041*
Fasting glucose(mmol/l) 82.18±11.79 117.59±34.02 .000*
Fasting insulin(U/mL) 8.94±3.66 10.37±6.93 .285
HOMA-IR 1.75±0.63 2.91±2.00c .002*
AGF(ng/mL) 52.30±35.59 113.30±69.92 .000*
BUN (mg/dL) 13.84±6.38 12.61±4.65 .330
Creatinine (mg/dL) 0.74±0.25 0.79±0.25 .465
Aspartate transaminase (IU/mL) 20.96±6.86 21.38±7.18 .798
Alanine transaminase (IU/mL) 20.18±6.85 20.61±6.71 .783
* Statistically significant, GDM; Gestational diabetes mellitus, BMI; Body mass index, 
HOMA-IR; Homeostasis Model of Assessment - Insulin Resistance, AGF; Angiopoietin-related Growth Factor, 
BUN; Blood urea nitrogen.
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Discussion
To	the	best	of	our	knowledge,	this	is	the	first	study	comparing	
AGF levels between patients with GDM and healthy pregnant 
controls.	In	the	current	study,	we	demonstrated	for	the	first	time	
that	 serum	 AGF	 levels	 were	 significantly	 higher	 in	 patients	
with	GDM	than	in	the	control	group.	Furthermore,	statistically	
significant	 positive	 correlation	 was	 found	 between	 AGF	 and	
HOMA-IR	and	serum	insulin	level	in	patients	with	GDM.	
In population studies, pregnant women with gestational 
diabetes	 present	 increased	 risk	 of	 pregnancy-associated	
hypertension	compared	with	non-diabetic	women	[8].	Moreover,	
pregnant	 patients	 with	 hypertension	 are	 at	 increased	 risk	 for	
developing	gestational	diabetes	mellitus	 [8].	There	 is	no	 study	
evaluating	 the	 association	 between	 GDM	 and	 AGF.	 On	 the	
other hand, the relationship between preeclampsia and AGF was 
evaluated	in	a	single	study	and	serum	AGF	level	was	found	to	
be	 higher	 in	 pregnant	women	with	 preeclampsia.	AGF	 has	 an	
effect	on	angiogenesis	and	metabolism	[9].	 In	 rats,	 ablation	of	
AGF	has	proved	to	cause	accumulation	of	lipid	within	the	liver	
and	skeletal	muscle.	These	rats	presented	also	higher	frequency	
of	insulin	resistance	and	obesity	[10].	In	transgenic	rats,	two-fold	
increase	 in	 concentrations	 of	 circulating	AGF	 caused	 elevated	
energy	 expenditure	 and	 improved	 insulin	 sensitivity	 and	 lipid	
profiles	[10].	However,	contrary	to	the	data	obtained	from	animal	
studies,	an	expected	favorable	effect	of	AGF	on	metabolism	was	
not	observed	in	humans.	In	the	studies	on	patients	with	diabetes	
mellitus type 2, serum AGF levels were observed to be higher, 
although	 it	 was	 expected	 to	 be	 lower	 in	 the	 study	 hypothesis	
[14].	
In another study, AGF levels were evaluated in 216 
individuals	with	metabolic	syndrome.	AGF	levels	were	found	to	
Table  I I .  Correlation between serum AGF levels and biochemical and anthropometric markers.
CONTROL group (n=33) GDM group (n=44)
r-value p-value r-value p-value
Age ―.063 .729 .173 .262
Gravidity .044 .810 .133 .389
Parity ―.008 .965 .118 .447
Gestational age .323 .067 .251 .100
Pregestational weight ―.146 .418 ―.173 .260
Gestational weight ―.128 .479 ―.102 .509
Pregestational BMI ―.225 .207 ―.133 .391
Gestational BMI ―.205 .252 ―.056 .717
Systolic blood pressure .157 .384 .029 .854
Diastolic blood pressure .298 .092 .020 .896
Mean arterial pressure .269 .130 .026 .869
Aspartate transaminase .090 .617 .063 .684
Alanine transaminase ―.078 .667 .050 .745
BUN ―.243 .173 ―.093 .549
Creatinine .140 .438 ―.238 .119
Fasting glucose .073 .687 .214 .162
Fasting insulin .256 .150 .448* .002
HOMA-IR .124 .492 .543* .000
* Statistically significant, GDM; Gestational diabetes mellitus, AGF; Angiopoietin-related Growth Factor, BMI; Body mass index, 
BUN; Blood urea nitrogen, HOMA-IR; Homeostasis Model of Assessment - Insulin Resistance,
Table III. Linear regression with serum AGF levels.
Independent variable Unstandardized β P-value
Gestational diabetes 
mellitus 18.957 0.006*
Insulin -0.881 0.686
HOMA-IR 20.995 0.010*
* Statistically significant, AGF; Angiopoietin-related Growth Factor, 
HOMA-IR; Homeostasis Model of Assessment - Insulin Resistance.
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be	higher	in	69	patients	with	metabolic	syndrome	when	compared	
to	controls.	Another	result	in	that	study	was	a	discovered	increase	
in insulin resistance in addition to increased AGF levels in the 
metabolic	syndrome	group.	 It	was	also	shown	 that	an	 increase	
in	the	AGF	levels	was	greater	in	women	[15].	In	our	study,	no	
assessment was done regarding the relation between AGF and 
gender,	as	only	women	in	the	third	trimester	of	pregnancy	were	
included.	Although	an	inverse	relation	was	reported	between	age	
and AGF in a study evaluating AGF in individuals with metabolic 
syndrome,	no	such	relation	was	found	in	our	study.	We	believe	
it	was	caused	by	the	differences	between	the	subjects	from	that	
study	and	 from	ours,	which	 included	only	pregnant	women	of	
similar	 ages.	 Contrary	 to	 favorable	 metabolic	 effects	 of	AGF	
in	the	animal	studies,	trials	on	human	subjects	[14,	15]	suggest	
that there is a negative relationship between insulin resistance 
and	AGF.	However,	it	was	shown	that	there	was	no	association	
between AGF levels and serum glucose or insulin levels in a 
study	 conducted	 on	 patients	 with	 preeclampsia	 [13].	 In	 that	
study,	serum	AGF	levels	were	found	to	be	higher	in	preeclamptic	
patients	 [13].	The	 authors	 proposed	 a	 theory	 that	 this	 increase	
occurs	 to	 compensate	 the	 effect	 of	 impaired	 angiogenesis	 and	
nitric	 oxide.	 In	 that	 study,	 another	 interesting	 finding	 was	 a	
decrease	 of	 the	AGF	 level	 6	months	 after	 the	 delivery.	 In	 our	
study, AGF levels were also higher and, actually, impaired 
glucose	 tolerance	may	be	 the	cause	of	 this	 increase.	However,	
scarcity	of	data	(there	have	been	only	2	studies	on	this	matter	so	
far	and	they	included	small	numbers	of	cases)	does	not	allow	to	
draw	definitive	conclusions.	
Namkung	 et	 al.	 reported	 that	 HOMA-IR	 index	 and	 BMI	
showed	 paradoxical	 correlation	 between	 the	 groups;	 being	
positive in the healthy group and negative in the metabolic 
syndrome	group.	They	also	reported	that	serum	AGF	levels	were	
significantly	higher	in	subjects	with	impaired	glucose	tolerance	
than	 in	 healthy	 controls	 but	 subjects	 with	 diabetes	 mellitus	
(β-cell	failure)	had	similar	 levels	compared	with	controls	(data	
not	 shown)	 [15].	 In	 another	 study,	 AGF	 serum	 levels	 were	
significantly	 increased	 in	 diabetic	 patients.	 It	 was	 also	 shown	
that	fasting	glucose	levels	had	positive	predictive	effect	on	AGF	
levels	independent	of	age,	sex,	GFR	and	BMI	[14].	Our	findings	
are	 consistent	 with	 these	 studies.	 Impaired	 glucose	 tolerance	
is	 thought	 to	 be	 more	 primarily	 effective	 than	 ß-cell	 failure	
in	 gestational	 diabetes	 mellitus,	 which	 is	 defined	 as	 glucose	
tolerance	developing	or	first	recognized	during	pregnancy	[16].	In	
our	study,	it	was	shown	that	serum	AGF	levels	were	significantly	
higher	in	subjects	with	GDM	and	HOMA-IR	value	has	a	positive	
predictive	effect	on	AGF	levels.	
Conclusion
There	are	several	limitations	to	the	present	study.	First,	this	
is	a	cross-sectional	study.	Second,	sample	size	is	relatively	small,	
particularly	 in	 the	 study	group.	According	 to	our	 results,	AGF	
levels	were	higher	in	patients	with	GDM.	This	does	not	support	
the	 results	 obtained	 in	 animal	 studies.	 In	 order	 to	 understand	
the	effects	of	AGF	on	metabolism	of	humans,	first	one	needs	to	
discover	the	factors	affecting	AGF	levels.	After	identifying	these	
factors,	 findings	 from	 further	 studies,	 including	 larger	 sample	
size,	will	provide	definitive	conclusions	about	metabolic	effects	
of	AGF,	such	as	obesity	and	insulin	resistance	in	humans.	
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